Here’s a startling fact: a significant number of breast cancers are being diagnosed in women under 40, a group often overlooked in routine screening recommendations. But here’s where it gets controversial—these younger women not only represent a substantial portion of cases, but their tumors are often more aggressive, raising urgent questions about current screening guidelines. And this is the part most people miss: nearly a quarter of all breast cancers diagnosed in a large New York imaging practice were in women under 50, with a striking 23% occurring in those under 40—a demographic not typically advised for regular mammograms.
In a retrospective review spanning 2014 to 2024, Stamatia Destounis, MD, of Elizabeth Wende Breast Care in Rochester, New York, analyzed nearly 1,800 breast cancer cases in women aged 18 to 49. The findings were eye-opening: younger patients under 40 faced higher rates of invasive tumors (84.7% vs. 77% in women 40-49), triple-negative disease (13.5% vs. 8.5%), and grade 3 tumors (46% vs. 29%). This isn’t just a statistic—it’s a call to action. As Destounis pointed out during the Radiological Society of North America (RSNA) meeting, these tumors are biologically aggressive, demanding a reevaluation of how we approach early detection and intervention for younger women.
But here’s the debate: Should screening guidelines be adjusted to include younger women, especially those at high risk? Current recommendations from the U.S. Preventive Services Task Force suggest mammograms every other year starting at 40, while the American Cancer Society allows for annual screening as early as 45, with an option to start at 40. Yet, these thresholds may not account for the rising incidence of breast cancer in younger populations, as highlighted by recent CDC and American Cancer Society data.
Destounis’s study, which included 1,798 breast cancers diagnosed in 1,290 women across seven outpatient facilities in Western New York, revealed that 20% to 24% of all breast tumors during the study period were in women under 50. The majority of these women were white (90%), and 21% had a family history of breast cancer. Interestingly, 41% of cancers were detected through screening, while 59% were found during diagnostic evaluations. The average tumor size was 22 mm for invasive and 27 mm for non-invasive cancers.
Among the cases, 80.6% were invasive, and a third were grade 3. Most tumors were hormone receptor (HR)-positive/HER2-negative (61.6%), followed by triple-negative (9.7%), HR-positive/HER2-positive (8.6%), and HR-negative/HER2-positive (4.9%). When asked about BRCA gene mutations in younger patients, Destounis noted that while genetic testing is recommended for all newly diagnosed patients, especially younger ones, most were not BRCA1 or BRCA2 positive. However, other mutations, such as PALB2 and PTEN, were identified, adding another layer of complexity to the discussion.
So, here’s the question: Should we be testing for a broader range of genetic mutations earlier, and should screening guidelines be expanded to include younger, high-risk women? The data suggests a pressing need for change, but it’s a topic that’s sure to spark differing opinions. What do you think? Should we rethink how we approach breast cancer screening for younger women, or are current guidelines sufficient? Let’s start the conversation—share your thoughts in the comments below.
